The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Amphastar plans to quadruple its production capacity at this location over the next three to five years.

A number of other drugmakers have rolled out similar plans to ramp up U.S. manufacturing in recent days, in the face of ...

AstraZeneca (AZN) said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have announced more than $200 billion combined in investments in the coming ...

Discover how pharmaceutical companies are utilising digital tools such as AI to enhance drug discovery and clinical development processes. Stay ahead of the curve with the latest advancements in R&D.

President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to ...

Stay ahead of the curve by exploring the key trends shaping pharmaceutical operations in 2025, including cybersecurity, efficiency, workforce management, and technology advancements. Learn more ...

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.